NCT06189963View on ClinicalTrials.gov

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Moderate Alzheimer Disease
Interventions
BIOLOGICAL

SNK01

SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

OTHER

Placebo

Sodium Lactate Hartmann's Solution

Trial Locations (5)

32804

NOT_YET_RECRUITING

AdventHealth Research Institute, Orlando

91206

RECRUITING

Behavioral Research Specialists, LLC, Glendale

91356

RECRUITING

Valiance Clinical Research, Tarzana

92705

RECRUITING

Syrentis Clinical Research, Santa Ana

K1Z 1G3

NOT_YET_RECRUITING

Ottawa Memory Clinic, Ottawa

Sponsors
All Listed Sponsors
lead

NKGen Biotech, Inc.

INDUSTRY

NCT06189963 - Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter